The European Commission has approved a change in treatment duration for Neurim Pharmaceuticals/Nycomed/Lundbeck's insomnia drug Circadin (melatonin), from three weeks to 13 weeks (three months), in patients aged 55 years and over with primary insomnia .
Circadin was first approved in the EU in 2007, where it is commercialised by Lundbeck and Nycomed (scripintellegence.com, 23...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?